Background: Patients with inflammatory bowel disease (IBD) suffer from various physical as well as psychological impairments, and patient education may help improve their well-being. Therefore, we developed a manualized education program for IBD patients addressing medical and psychological issues. This study aimed to evaluate it in a large controlled trial. Methods: A total of 181 IBD outpatients participated in a prospective, randomized, waitlist-controlled trial; assessments were made before as well as 2 weeks and 3 months after intervention. Analysis of covariance was used to assess intervention effects on disease-related worries and concerns (primary outcome), fear of progression, coping with anxiety, health competencies, health-related quality of life (HRQoL), perceived disease activity, symptoms of depression and anxiety, disease-related knowledge, and coping strategies. Participants' satisfaction with the program was also evaluated. Results: At 2 weeks and 3 months after intervention, we found significant large effects of our education program on skill and technique acquisition, knowledge, and coping with IBD. Moreover, we found significant medium effects on disease-related worries and concerns, fear of progression, coping with anxiety, constructive attitudes and approaches, as well as coping with disease-related negative emotions. The number of coping strategies used was significantly higher at 3 months. We did not find any effects on perceived disease activity, HRQoL, positive and active engagement in life, or symptoms of anxiety and depression. The program was rated very favorably by the attendees. Conclusion: Our education program contributed to improvements in psychological distress, self-management skills, and coping and was appreciated by its attendees.

1.
Stange EF (ed): Entzündliche Darmerkrankungen. Klinik, Diagnostik und Therapie. Stuttgart, Schattauer, 2015.
2.
Mittermaier C, Dejaco C, Waldhoer T, et al: Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med 2004;66:79-84.
3.
Mardini HE, Kip KE, Wilson JW: Crohn's disease: a two-year prospective study of the association between psychological distress and disease activity. Dig Dis Sci 2004;49:492-497.
4.
Maunder RG, Levenstein S: The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence. Curr Mol Med 2008;8:247-252.
5.
Drossman DA, Leserman J, Li ZM, Mitchell CM, Zagami EA, Patrick DL: The Rating Form of IBD Patient Concerns: a new measure of health status. Psychosom Med 1991;53:701-712.
6.
Mussell M, Böcker U, Nagel N, Singer MV: Predictors of disease-related concerns and other aspects of health-related quality of life in outpatients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2004;16:1273-1280.
7.
Bernklev T, Jahnsen J, Henriksen M, et al: Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2006;12:402-412.
8.
Hardt J, Muche-Borowski C, Conrad S, Balzer K, Bokemeyer B, Raspe H: Chronisch entzündliche Darmerkrankungen als multifokale Erkrankungen: körperliche und psychosoziale Probleme von Patienten mit CED. Ergebnisse eines Fragebogen-Surveys. Z Gastroenterol 2010;48:381-391.
9.
Hüppe A, Langbrandtner J, Raspe H: Komplexe psychosoziale Problemlagen bei Morbus Crohn und Colitis ulcerosa - fragebogengestütztes Assessment als erster Schritt zur Aktivierung von Patientinnen und Patienten. Z Gastroenterol 2013;51:257-270.
10.
Mikocka-Walus A, Knowles SR, Keefer L, Graff L: Controversies revisited: a systematic review of depression and anxiety with inflammatory bowel diseases. Inflamm Bowel Dis 2016;22:752-762.
11.
Warsi A, Wang PS, LaValley MP, Avorn J, Solomon DH: Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. Arch Intern Med 2004;164:1641-1649.
12.
De Ridder D, Schreurs K: Developing interventions for chronically ill patients. Clin Psychol Rev 2001;21:205-240.
13.
Baars JE, Siegel CA, van't Spijker A, Markus T, Kuipers EJ, van der Woude CJ: Inflammatory bowel disease-patients are insufficiently educated about the basic characteristics of their disease and the associated risk of colorectal cancer. Dig Liver Dis 2010;42:777-784.
14.
Conrad S, Hüppe A, Raspe H: Zu welchen Themen wünschen Patientinnen und Patienten mit Morbus Crohn oder Colitis ulcerosa mehr Informationen und welche eigene Rolle bevorzugen sie bei medizinischen Behandlungsentscheidungen? Ergebnisse einer Betroffenenbefragung in Deutschland. Z Gastroenterol 2012;50:364-372.
15.
van Assche G, Dignass A, Reinisch W, et al: The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010;4:63-101.
16.
van Assche G, Dignass A, Bokemeyer B, et al: Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013;7:1-33.
17.
Dignass A, Preiß JC, Aust DE, et al: Aktualisierte Leitlinie zur Diagnostik und Therapie der Colitis ulcerosa 2011 - Ergebnisse einer evidenzbasierten Konsensuskonferenz. Z Gastroenterol 2011;49:1276-1341.
18.
Preiß JC, Bokemeyer B, Buhr HJ, et al: Aktualisierte S3-Leitlinie “Diagnostik und Therapie des M. Crohn” 2014. Z Gastroenterol 2014;52:1431-1484.
19.
Mussell M, Böcker U, Nagel N, Olbrich R, Singer MV: Reducing psychological distress in patients with inflammatory bowel disease by cognitive-behavioural treatment: exploratory study of effectiveness. Scand J Gastroenterol 2003;38:755-762.
20.
Jäghult S, Larson J, Wredling R, Kapraali M: A multiprofessional education programme for patients with inflammatory bowel disease: a randomized controlled trial. Scand J Gastroenterol 2007;42:1452-1459.
21.
Krebs H, Kachel F, Faller H: Der Fragebogen zur Erfassung der Sorgen von Patienten mit chronisch-entzündlichen Darmerkrankungen (IBD Patient Concerns): Ergebnisse zur Reliabilität und Validität einer deutschen Version. Prax Klin Verhaltensmed Rehab 1998;41:50-55.
22.
Mehnert A, Herschbach P, Berg P, Henrich G, Koch U: Progredienzangst bei Brustkrebspatientinnen - Validierung der Kurzform des Progredienzangstfragebogens PA-F-KF. Z Psychosom Med Psychother 2006;52:274-288.
23.
Herschbach P, Berg P, Dankert A, et al: Fear of progression in chronic diseases: psychometric properties of the Fear of Progression Questionnaire. J Psychosom Res 2005;58:505-511.
24.
Osborne RH, Elsworth GR, Whitfield K: The Health Education Impact Questionnaire (heiQ): an outcomes and evaluation measure for patient education and self-management interventions for people with chronic conditions. Patient Educ Couns 2007;66:192-201.
25.
Schuler M, Musekamp G, Faller H, et al: Assessment of proximal outcomes of self-management programs: translation and psychometric evaluation of a German version of the Health Education Impact Questionnaire (heiQ™). Qual Life Res 2013;22:1391-1403.
26.
Janke KH, Raible A, Bauer M, et al: Questions on life satisfaction (FLZM) in inflammatory bowel disease. Int J Colorectal Dis 2004;19:343-353.
27.
Best WR, Becktel JM, Singleton JW, Kern F: Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-444.
28.
Rachmilewitz D: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298:82-86.
29.
Bullinger M, Kirchberger I: SF-36 Fragebogen zum Gesundheitszustand. Göttingen, Hogrefe, 1998.
30.
Löwe B, Wahl I, Rose M, et al: A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. J Affect Disord 2010;122:86-95.
31.
Kennedy AP, Nelson E, Reeves D, et al: A randomised controlled trial to assess the effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease. Gut 2004;53:1639-1645.
32.
Cohen J: Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ, Erlbaum, 1988.
33.
Schreiber S, Haemling J, Wedel S, Nikolaus SN, Buhr HJ, Raedler A: Efficacy of patient education in chronic inflammatory bowel disease in a prospective controlled multicenter trial. Gastroenterology 1999;116:A3535.
34.
Waters BM, Jensen L, Fedorak RN: Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. Can J Gastroenterol 2005;19:235-244.
35.
Bregenzer N, Lange A, Fürst A, Gross V, Schölmerich J, Andus T: Patient education in inflammatory bowel disease does not influence patients' knowledge and long-term psychosocial well-being. Z Gastroenterol 2005;43:367-371.
36.
Robinson A, Thompson DG, Wilkin D, Roberts C; the Northwest Gastrointestinal Research Group: Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. Lancet 2001;358:976-981.
37.
Larsson K, Sundberg Hjelm M, Karlbom U, Nordin K, Anderberg UM, Lööf L: A group-based patient education programme for high-anxiety patients with Crohn's disease or ulcerative colitis. Scand J Gastroenterol 2003;38:763-769.
38.
Smith GD, Watson R, McRorie D, et al: Impact of a nurse-led counselling service on quality of life in patients with inflammatory bowel disease. J Adv Nurs 2002;38:152-160.
39.
Schwarz SP, Blanchard EB: Evaluation of a psychological treatment for inflammatory bowel disease. Behav Res Ther 1991;29:167-177.
40.
Díaz Sibaja MA, Comeche Moreno MI, Mas Hesse B: Protocolized cognitive-behavioral group therapy for inflammatory bowel disease. Rev Esp Enferm Dig 2007;99:593-598.
41.
Oxelmark L, Magnusson A, Löfberg R, Hillerås P: Group-based intervention program in inflammatory bowel disease patients: effects on quality of life. Inflamm Bowel Dis 2007;13:182-190.
42.
Timmer A, Preiss JC, Motschall E, Rücker G, Jantschek G, Moser G: Psychological interventions for treatment of inflammatory bowel disease (review). Cochrane Libr 2011;5:1-132.
43.
Barlow C, Cooke D, Mulligan K, Beck E, Newman S: A critical review of self-management and educational interventions in inflammatory bowel disease. Gastroenterol Nurs 2010;33:11-18.
44.
Conley S, Redeker N: A systematic review of self-management interventions for inflammatory bowel disease. J Nurs Scholarsh 2016;48:118-127.
45.
Milne B, Joachim G, Niedhardt J: A stress management programme for inflammatory bowel disease patients. J Adv Nurs 1986;11:561-567.
46.
Keefer L, Kiebles JL, Martinovich Z, Cohen E, Van Denburg A, Barrett TA: Behavioral interventions may prolong remission in patients with inflammatory bowel disease. Behav Res Ther 2011;49:145-150.
47.
Eaden JA, Abrams K, Mayberry JF: The Crohn's and Colitis Knowledge Score: a test for measuring patient knowledge in inflammatory bowel disease. Am J Gastroenterol 1999;94:3560-3566.
48.
Jones SC, Gallacher B, Lobo AJ, Axon AT: A patient knowledge questionnaire in inflammatory bowel disease. J Clin Gastroenterol 1993;17:21-24.
49.
Janke KH, Klump B, Steder-Neukamm U, Hoffmann J, Häuser W: Validierung der Deutschen Version (Kompetenznetz “Chronisch entzündliche Darmerkrankungen”) des Inflammatory Bowel Disease Questionnaire IBDQ-D. Psychother Psychosom Med Psychol 2006;56:291-298.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.